X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (28) 28
humans (26) 26
life sciences (20) 20
cancer (18) 18
female (17) 17
male (16) 16
middle aged (15) 15
lymphomas (14) 14
adult (13) 13
aged (13) 13
oncology (13) 13
treatment outcome (12) 12
hematology (10) 10
prognosis (10) 10
[ sdv.can ] life sciences [q-bio]/cancer (9) 9
chemotherapy (9) 9
analysis (8) 8
hemic and lymphatic diseases (8) 8
aged, 80 and over (7) 7
antineoplastic agents - therapeutic use (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
pathology (7) 7
rituximab (7) 7
survival (7) 7
[ sdv ] life sciences [q-bio] (6) 6
abridged index medicus (6) 6
b-cell lymphoma (6) 6
biopsy (6) 6
disease-free survival (6) 6
neoplasm staging (6) 6
diagnosis (5) 5
expression (5) 5
follicular lymphoma (5) 5
france (5) 5
immunohistochemistry (5) 5
lymphoma, follicular - drug therapy (5) 5
lymphoma, large b-cell, diffuse - pathology (5) 5
surgery (5) 5
adolescent (4) 4
antineoplastic agents (4) 4
biomarkers, tumor - analysis (4) 4
care and treatment (4) 4
drug administration schedule (4) 4
follow-up (4) 4
immune system diseases (4) 4
medical research (4) 4
medicine, experimental (4) 4
mesh : humans (4) 4
mutation (4) 4
non-hodgkins-lymphoma (4) 4
patients (4) 4
proportional hazards models (4) 4
prospective studies (4) 4
retrospective studies (4) 4
survival analysis (4) 4
time factors (4) 4
tumors (4) 4
young adult (4) 4
[sdv.can]life sciences [q-bio]/cancer (3) 3
[sdv]life sciences [q-bio] (3) 3
antineoplastic agents - administration & dosage (3) 3
breast cancer (3) 3
breast neoplasms - pathology (3) 3
cohort studies (3) 3
confidence intervals (3) 3
cytarabine - administration & dosage (3) 3
epidemiology (3) 3
hyperplasia (3) 3
lymphocytes b (3) 3
lymphoma (3) 3
lymphoma, follicular - mortality (3) 3
lymphoma, large b-cell, diffuse - therapy (3) 3
lymphoma, non-hodgkin - therapy (3) 3
mantle cell lymphoma (3) 3
medical prognosis (3) 3
medicine & public health (3) 3
mesh : aged (3) 3
mesh : drug administration schedule (3) 3
mesh : female (3) 3
mesh : male (3) 3
mesh : middle aged (3) 3
methotrexate (3) 3
methotrexate - administration & dosage (3) 3
microenvironment (3) 3
relapse (3) 3
rituximab - administration & dosage (3) 3
t cells (3) 3
acute leukemias (2) 2
antibodies, monoclonal, murine-derived - therapeutic use (2) 2
antimitotic agents (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
atypical ductal hyperplasia (2) 2
automation (2) 2
biopsy, needle (2) 2
bone marrow neoplasms - drug therapy (2) 2
brain (2) 2
breast (2) 2
burkitt lymphoma - chemistry (2) 2
burkitt lymphoma - diagnosis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2016, Volume 34, Issue 25, pp. 3023 - 3030
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10036, pp. 2402 - 2411
Summary Background Short intensive chemotherapy is the standard of care for adult patients with Burkitt's leukaemia or lymphoma. Findings from single-arm... 
Internal Medicine | MEDICINE, GENERAL & INTERNAL | CODOX-M/IVAC | CLEAVED-CELL LYMPHOMA | ACUTE-LYMPHOBLASTIC-LEUKEMIA | MULTIAGENT CHEMOTHERAPY | ADOLESCENTS | PLUS RITUXIMAB | NON-HODGKIN-LYMPHOMA | SURVIVAL RATE | PEDIATRIC-ONCOLOGY-SOCIETY | CHILDREN | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Injections, Intravenous | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Patient Selection | Burkitt Lymphoma - pathology | Hydrocortisone - administration & dosage | Vincristine - administration & dosage | Adult | Female | France | Odds Ratio | Burkitt Lymphoma - drug therapy | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Drug Administration Schedule | Biomarkers, Tumor - analysis | Proportional Hazards Models | Treatment Outcome | Burkitt Lymphoma - diagnosis | Burkitt Lymphoma - chemistry | Cytarabine - administration & dosage | Rituximab - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Methotrexate - administration & dosage | Aged | Bone Marrow Neoplasms - drug therapy | Neoplasm Staging | Central Nervous System Neoplasms - drug therapy | Methylprednisolone - administration & dosage | Chemotherapy | Leukemia | Lymphomas | Adults | Epidemiology | Biometry | Cancer | Survival analysis | Biomedical research | Dehydrogenases | Medical prognosis | Clinical trials | Life Sciences
Journal Article
Journal Article
Blood, ISSN 0006-4971, 08/2018, Volume 132, Issue 5, pp. 510 - 520
Activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL) is an aggressive lymphoproliferative disorder involving chronic NF-κB activation. Several mutations... 
Life Sciences | Cancer
Journal Article
British journal of haematology, ISSN 0007-1048, 08/2019
The prognostic value of cell of origin (COO) classification and BCL2 expression is not well established in diffuse large B-cell lymphoma (DLBCL) patients with... 
Journal Article
EMBO Molecular Medicine, ISSN 1757-4676, 02/2016, Volume 8, Issue 2, pp. 96 - 104
DCC (Deleted in Colorectal Carcinoma) has been demonstrated to constrain tumor progression by inducing apoptosis unless engaged by its ligand netrin‐1. This... 
dependence receptors | apoptosis | non‐Hodgkin lymphoma | DCC | netrin‐1 | Non-Hodgkin lymphoma | Dependence receptors | Netrin-1 | Apoptosis | SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | NEOPLASMS | non-Hodgkin lymphoma | CANCER | MALIGNANCIES | MICE | DCC GENE | RECEPTORS | TUMORIGENESIS | EXPRESSION | netrin-1 | DCC Receptor | Tumor Suppressor Proteins - metabolism | Lymphoma, Large B-Cell, Diffuse - pathology | Tumor Suppressor Proteins - antagonists & inhibitors | Humans | Lymphoma, Mantle-Cell - pathology | Receptors, Cell Surface - metabolism | Mice, Transgenic | Antineoplastic Agents - administration & dosage | Antibodies - pharmacology | Antibodies - administration & dosage | Lymphoma, Large B-Cell, Diffuse - therapy | Lymphoma, Mantle-Cell - therapy | Animals | Heterografts | Cell Line, Tumor | Nerve Growth Factors - antagonists & inhibitors | Protein Binding | Antineoplastic Agents - pharmacology | Mice | Disease Models, Animal | Development and progression | Lymphomas | Genetic engineering | Analysis | Colorectal cancer | Spleen | Lymphatic system | Cell survival | Tumor cells | Colorectal carcinoma | Transgenic mice | Lymphocytes B | Mantle cell lymphoma | Conflicts of interest | Breast | Ligands | Regulation | Survival factor | DCC protein | Laboratory animals | Cancer | Tumors | Life Sciences | Haematology | Report | Reports
Journal Article
Human Pathology, ISSN 0046-8177, 2017, Volume 64, pp. 128 - 136
Journal Article
Journal Article